− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected –
− Progression into clinical studies planned by the end of 2024 –
“We’re pleased to nominate ABI-6250 as a development candidate targeting chronic HDV infection, the most severe form of viral hepatitis,” said
HDV is a virus that infects liver cells in people who are also infected with hepatitis B virus (HBV). Patients with chronic HDV infection experience much higher rates of cirrhosis and liver cancer than those with chronic HBV infection only. In preclinical studies, ABI-6250 inhibited the interaction of HDV with sodium taurocholate co-transporting polypeptide (NTCP), the host receptor used by HBV/HDV to enter liver cells. Inhibiting viral entry by blocking NTCP is a clinically validated target for reducing HDV viremia and liver injury in patients.
In preclinical studies, ABI-6250 demonstrated low nanomolar potency against all tested HBV/HDV genotypes, favorable selectivity for NTCP versus other bile acid transporters, good oral bioavailability and a pharmacokinetic profile projected to support once-daily oral dosing. Assembly Bio plans to present data for ABI-6250 at future scientific conferences.
About Assembly Biosciences
Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the
Contacts
Investor and Corporate:
SVP, Investor Relations, Corporate Affairs and Alliance Management
(415) 738-2992
sryan@assemblybio.com
Media:
Sam Brown Inc.
Hannah Hurdle
(805) 338-4752
ASMBMedia@sambrown.com
Source:
2023 GlobeNewswire, Inc., source